Erythropoietin improves glucose metabolism and pancreatic β-cell damage in experimental diabetic rats

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5391-5398

  Chen, Li Na ^a   Sun, Qiang ^a   Liu, Shu Qing ^a   Hu, Hao ^a   Lv, Juan ^a   Ji, Wen Jun ^a   Wang, Meng ^a   Chen, Ming Xia ^a   Zhou, Jun ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti oxidation; Erythropoietin; Experimental diabetic rats; Glucose metabolism; Pancreatic cells

Indexed keywords

ALANINE; ERYTHROPOIETIN; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SELENIUM; STREPTOZOCIN; SUPEROXIDE DISMUTASE; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL DAMAGE; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL DIABETES MELLITUS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; INVESTIGATIVE PROCEDURES; LIPID DIET; LOW DRUG DOSE; MALE; MITOCHONDRION; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; SECRETORY GRANULE; SELENIUM BLOOD LEVEL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ULTRASTRUCTURE; ANIMAL; BLOOD; CARBOHYDRATE METABOLISM; DIET RESTRICTION; DISEASE MODEL; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; HEMATOPOIESIS; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FASTING; GLUCOSE; GLUCOSE TOLERANCE TEST; GLUTATHIONE PEROXIDASE; HEMATOPOIESIS; INSULIN; INSULIN-SECRETING CELLS; MALE; MALONDIALDEHYDE; RATS; SELENIUM; SUPEROXIDE DISMUTASE;

EID: 84940544330     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4006     Document Type: Article

References (41)

1. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M and Diederich M: Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 82: 1291-1303, 2011.
2. Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R and Noguchi CT: Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 15: 10296-10333, 2014.
3. Choi D, Retnakaran R and Woo M: The extra-hematopoietic role of erythropoietin in diabetes mellitus. Curr Diabetes Rev 7: 284-290, 2011.
4. Choi D, Retnakaran R and Woo M: The extra-hematopoietic role of erythropoietin in diabetes mellitus. Curr Diabetes Rev 7: 284-290, 2011.
5. Chikuma M, Masuda S, Kobayashi T, Nagao M and Sasaki R: Tissue-specifc regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab 279: E1242-E1248, 2000.
6. Lamon S, Zacharewicz E, Stephens AN and Russell AP: EPO-receptor is present in mouse C2C12 and human primary skeletal muscle cells but EPO does not Influence myogenesis. Physiol Rep 2: e00256, 2014.
7. Dimitrijevic ZM, Cvetkovic T P, Djordjevic VM, Pavlovic DD, Stefanovic NZ, Stojanovic IR, Paunovic GJ and Velickovic-Radovanovic RM: How the duration period of erythropoietin treatment Influences the oxidative status of hemo-dialysis patients. Int J Med Sci 9: 808-815, 2012.
8. Nairz M, Sonnweber T, Schroll A, Theurl I and Weiss G: The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14: 238-246, 2012.
9. Chen S, Li J, Peng H, Zhou J and Fang H: Administration of erythropoietin exerts protective effects against glucocor-ticoid-induced osteonecrosis of the femoral head in rats. Int J Mol Med 33: 840-848, 2014.
10. Stoyanoff TR, Todaro JS, Aguirre MV, Zimmermann MC and Brandan NC: Amelioration of lipopolysaccharide-induced acute kidney injury by erythropoietin: Involvement of mitochondria-regulated apoptosis. Toxicology 318: 13-21, 2014.
11. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al; China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 362: 1090-1101, 2010.
12. Janghorbani M and Amini M: Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan, Iran. Endokrynol Pol 63: 372-380, 2012.
13. Ohshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, Min LJ, Ogimoto A, Dahlöf B, Steckelings UM, Unger T, et al: Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One 7: e48387, 2012.
14. Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L and Ricordi C: Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 75: 1356-1360, 2003.
15. Kwon MS, Kim MH, Kim SH, Park KD, Yoo SH, Oh IU, Pak S and Seo YJ: Erythropoietin exerts cell protective effect by activating PI3K/Akt and MAPK pathways in C6 Cells. Neurol Res 36: 215-223, 2014.
16. Fenjves ES, Ochoa MS, Gay-Rabinstein C, Molano RD, Pileggi A, Mendez AJ, Inverardi L and Ricordi C: Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation 77: 13-18, 2004.
17. Wietecha-Posłuszny R, Lech T and Koscielniak P: Application of three spectrometric methods to total selenium determination in postmortem material in a case of acute selenium compound poisoning. J Forensic Sci 56: 518-521, 2011.
18. Wang Q, Pfster F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y and Hammes HP: Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia 53: 1227-1238, 2010.
19. Benstoem C, Goetzenich A, Kraemer S, Borosch S, Manzanares W, Hardy G and Stoppe C: Selenium and its supplementation in cardiovascular disease-what do we know? Nutrients 7: 3094-3118, 2015.
20. Christensen B, Nellemann B, Larsen MS, Thams L, Sieljacks P, Vestergaard PF, Bibby BM, Vissing K, Stødkilde-Jørgensen H, Pedersen SB, et al: Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: A randomized placebo controlled trial. Am J Physiol Endocrinol Metab 305: E879-E889, 2013.
21. Kristensen PL, Høi-Hansen T, Olsen N V, Pedersen-Bjergaard U and Thorsteinsson B: Erythropoietin during hypoglycaemia in type 1 diabetes: Relation to basal renin-angiotensin system activity and cognitive function. Diabetes Res Clin Pract 85: 75-84, 2009.
22. Wang L, Teng R, Di L, Rogers H, Wu H, Kopp JB and Noguchi CT: PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 62: 4122-4131, 2013.
23. Pan Y, Shu JL, Gu HF, Zhou DC, Liu XL, Qiao QY, Fu SK, Gao FH and Jin HM: Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol 367: 116-123, 2013.
24. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU and Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006.
25. Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, et al: Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes 61: 1726-1733, 2012.
26. Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B and Mirmira RG: Islet β-cell endoplasmic reticulum stress precedes the onset of 1 diabetes in the nonobese diabetic mouse model. Diabetes 61: 818-827, 2012.
27. He H, Wu T, Xiong J, Chen K and Mo Z: Effect of erythropoietin on the proliferation and apoptosis of neonatal porcine islet cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35: 1115-1122, 2010.
28. Shuai H, Zhang J, Zhang J, Xie J, Zhang M, Yu Y and Zhang L: Erythropoietin protects pancreatic β-cell line NIT-1 cells against cytokine-induced apoptosis via phosphatidylinositol 3-kinase/Akt signaling. Endocr Res 36: 25-34, 2011.
29. Yan LJ: Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. J Diabetes Res 2014: 137919, 2014.
30. Yu T, Li L, Bi Y, Liu Z, Liu H and Li Z: Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats. J Pharm Pharmacol 66: 1150-1160, 2014.
31. Luo YH, Li ZD, Liu LX and Dong GH: Pretreatment with erythropoietin reduces hepatic ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int 8: 294-299, 2009.
32. Yang FL, Subeq YM, Chiu YH, Lee R P, Lee CJ and Hsu BG: Recombinant human erythropoietin reduces rhabdomy-olysis-induced acute renal failure in rats. Injury 43: 367-373, 2012.
33. Liu N, Tian J, Wang W, Cheng J, Hu D and Zhang J: Effect and mechanism of erythropoietin on mesenchymal stem cell proliferation in vitro under the acute kidney injury microenvironment. Exp Biol Med (Maywood) 236: 1093-1099, 2011.
34. Stapleton SR: Selenium: An insulin-mimetic. Cell Mol Life Sci 57: 1874-1879, 2000.
35. Rocourt CR and Cheng WH: Selenium supranutrition: Are the potential benefts of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients 5: 1349-1365, 2013.
36. Wang C, Yang S, Zhang N, Mu Y, Ren H, Wang Y and Li K: Long-term supranutritional supplementation with selenate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyperinsulinemia in diabetic db/db mice. PLoS One 9: e101315, 2014.
37. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfeld DL and Gladyshev VN: Both maximal expression of selenoproteins and selenoprotein defciency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal 14: 2327-2336, 2011.
38. Stranges S, Sieri S, Vinceti M, Grioni S, Guallar E, Laclaustra M, Muti P, Berrino F and Krogh V: A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health 10: 564, 2010.
39. Thomas MC: The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol 26: 275-282, 2006.
40. Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano H Y, Wagner KU, Wu H, et al: Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 207: 2831-2842, 2010.
41. Wang Q, Gorbey S, Pfster F, Höger S, Dorn-Beineke A, Krügel K, Berrone E, Wu L, Korff T, Lin J, et al: Long-term treatment with suberythropoietic Epo is vaso-and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 27: 769-782, 2011.